ArticleMolecules (Basel, Switzerland)2022
Bis-Cinnamamide Derivatives as APE/Ref-1 Inhibitors for the Treatment of Human Melanoma.
Razan Alhazmi, Shirley Tong, Shaban Darwish, Elina Khanjani, Bharti Khungar, Swati Chawla, Zhonghui Zheng, Richard Chamberlin, Keykavous Parang, Sun Yang
Open access · goldAbstract read
In one paragraphArticle in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors at 3 institutions in 1 country.
Razan AlhazmiCenter for Targeted Drug Delivery, Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA 92618, USA.
Shirley TongCenter for Targeted Drug Delivery, Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA 92618, USA.ORCID 0000-0001-7026-7905 Shaban DarwishCenter for Targeted Drug Delivery, Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA 92618, USA.
Elina KhanjaniCenter for Targeted Drug Delivery, Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA 92618, USA.
Bharti KhungarCenter for Targeted Drug Delivery, Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA 92618, USA.
Swati ChawlaCenter for Targeted Drug Delivery, Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA 92618, USA.
Zhonghui ZhengDepartment of Pharmaceutical Sciences, University of California Irvine, Irvine, CA 92697, USA.
Richard ChamberlinDepartment of Pharmaceutical Sciences, University of California Irvine, Irvine, CA 92697, USA.
Keykavous ParangCenter for Targeted Drug Delivery, Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA 92618, USA.ORCID 0000-0001-8600-0893 Sun YangDepartment of Pharmacy Practice, Chapman University School of Pharmacy, Irvine, CA 92618, USA.ORCID 0000-0002-8463-7468 Target (United States) · USUniversity of California, Irvine · USChapman University · US
Funding
The Development of Novel Mechanistically-based APE/Ref-1 Redox InhibitorsK08CA179084 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI YANG, SUN · 2014 to 2018
$569kNCI NIH HHS K08CA179084Wellcome Trust
6 · The paper itselfAbstract
Human malignant melanoma exhibits imbalances in redox status, leading to activation of many redox-sensitive signaling pathways. APE/Ref-1 is a multifunctional protein that serves as a redox chaperone that regulates many nuclear transcription factors and is an important mechanism in cancer cell survival of oxidative stress. Previous studies showed that APE/Ref-1 is a potential druggable target for melanoma therapy. In this study, we synthesized a novel APE/Ref-1 inhibitor, bis-cinnamoyl-1,12-dodecamethylenediamine (
Indexed as
HominidaeMelanomaAnimalsCinnamatesDNA-(Apurinic or Apyrimidinic Site) LyaseHumansHydrogen PeroxideMicecinnamamideCinnamatesDNA-(Apurinic or Apyrimidinic Site) LyaseHydrogen PeroxideAPE/Ref-1human melanomareactive oxygen species (ROS)redox regulationsmall molecular inhibitors
Identifiers
PMID35566022
PMCPMC9103902
OpenAlexW4224311664
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390